New test can predict return of cancer

Apr 28, 2006

U.S. regulators have approved a test that reportedly can predict who are at high risk for a return of cancer after surgical removal of the prostate gland.

The test, known as Prostate PX, uses advanced computer technology and digital imaging to determine an individual's risk for a recurrence of cancer, reports The Washington Times.

The test, produced by Aureon Laboratories of Yonkers, N.Y., has been approved by the U.S. Food and Drug Administration and is being marketed around the country, the report said.

"Prostate cancer is the most diagnosed cancer in U.S. men, with about 230,000 diagnoses yearly. Of those, 90,000 to 100,000 men undergo a prostatectomy, or surgical removal of the prostate," said Rob Shovlyn with Aureon Laboratories.

The Times reported about 15 percent of post-prostatectomy patients experience a return of cancer. But, until now, it has been difficult for doctors to identify patients who fall into this high-risk category.

Copyright 2006 by United Press International

Explore further: Rare earth nanocrystals and infrared light can reveal small cancerous tumors and cardiovascular lesions

add to favorites email to friend print save as pdf

Related Stories

Big data tamed with the cloud

Sep 08, 2014

Big data: it's the hot topic these days, promising breakthroughs in just about every field, from medicine to marketing to machine learning and more. But for many of us, the problems of managing big data hit ...

Light of life

Aug 27, 2014

A fluorescent microscopic view of cells from a type of bone cancer, being studied for a future trip to deep space – aiming to sharpen our understanding of the hazardous radiation prevailing out there.

Recommended for you

Blood biomarker may detect lung cancer

6 minutes ago

A new study shows that patients with stage I to stage III non-small cell lung cancer have different metabolite profiles in their blood than those of patients who are at risk but do not have lung cancer. The study abstract ...

User comments : 0